P J Jenkins

Summary

Affiliation: Queen Mary
Country: UK

Publications

  1. ncbi Doping in sport
    Paul Jenkins
    Department of Endocrinology, St Bartholomew's Hospital, London EC1A 7BE, UK
    Lancet 360:99-100. 2002
  2. ncbi Acromegaly and cancer
    Paul J Jenkins
    Department of Endocrinology, St Bartholomew s Hospital, London, UK
    Horm Res 62:108-15. 2004
  3. ncbi Differential expression of IGF-binding protein-3 in normal and malignant colon and its influence on apoptosis
    P J Jenkins
    Department of Endocrinology, William Harvey Research Institute, Barts and the London Queen Mary s School of Dentistry, John Vane Building, Charterhouse Square, UK
    Endocr Relat Cancer 12:891-901. 2005
  4. ncbi Cancers associated with acromegaly
    Paul J Jenkins
    Department of Endocrinology, St Bartholomew s Hospital, London, UK
    Neuroendocrinology 83:218-23. 2006
  5. ncbi Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly
    P J Jenkins
    Department of Endocrinology, St Bartholomew s Hospital, London EC1A 7BE, United Kingdom
    J Clin Endocrinol Metab 91:1239-45. 2006
  6. ncbi Does growth hormone cause cancer?
    P J Jenkins
    Departments of Endocrinology, St Bartholomew s Hospital, London, UK
    Clin Endocrinol (Oxf) 64:115-21. 2006
  7. ncbi Evidence for a link between IGF-I and cancer
    Paul J Jenkins
    Department of Endocrinology, St Bartholomew s Hospital, London EC1A 7BE, UK
    Eur J Endocrinol 151:S17-22. 2004
  8. ncbi Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly
    P J Jenkins
    Department of Endocrinology, St Bartholomew s Hospital, London, United Kingdom
    J Clin Endocrinol Metab 85:3218-21. 2000
  9. ncbi Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors
    G Kaltsas
    Department of Endocrinology, St. Bartholomew's Hospital, London, United Kingdom EC1A 7BE
    J Clin Endocrinol Metab 86:895-902. 2001
  10. ncbi Increased levels of insulin-like growth factor binding protein-2 in sera and tumours from patients with colonic neoplasia with and without acromegaly
    F Miraki-Moud
    Department of Endocrinology, St. Bartholomew's Hospital, London, UK
    Clin Endocrinol (Oxf) 54:499-508. 2001

Collaborators

Detail Information

Publications38

  1. ncbi Doping in sport
    Paul Jenkins
    Department of Endocrinology, St Bartholomew's Hospital, London EC1A 7BE, UK
    Lancet 360:99-100. 2002
  2. ncbi Acromegaly and cancer
    Paul J Jenkins
    Department of Endocrinology, St Bartholomew s Hospital, London, UK
    Horm Res 62:108-15. 2004
    ....
  3. ncbi Differential expression of IGF-binding protein-3 in normal and malignant colon and its influence on apoptosis
    P J Jenkins
    Department of Endocrinology, William Harvey Research Institute, Barts and the London Queen Mary s School of Dentistry, John Vane Building, Charterhouse Square, UK
    Endocr Relat Cancer 12:891-901. 2005
    ..These effects are mediated in part by the PI-3K pathway in contrast to the MAP kinase pathway used by IGF-I...
  4. ncbi Cancers associated with acromegaly
    Paul J Jenkins
    Department of Endocrinology, St Bartholomew s Hospital, London, UK
    Neuroendocrinology 83:218-23. 2006
    ..However, these associations have been based mostly on small epidemiological surveys and circumstantial evidence. Large-scale epidemiological studies are required to clarify this issue...
  5. ncbi Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly
    P J Jenkins
    Department of Endocrinology, St Bartholomew s Hospital, London EC1A 7BE, United Kingdom
    J Clin Endocrinol Metab 91:1239-45. 2006
    ..There has been recent controversy as to the effectiveness of conventional pituitary irradiation in reducing circulating GH levels to less than 2.5 ng/ml and/or normalization of serum IGF-I...
  6. ncbi Does growth hormone cause cancer?
    P J Jenkins
    Departments of Endocrinology, St Bartholomew s Hospital, London, UK
    Clin Endocrinol (Oxf) 64:115-21. 2006
    ..Such a restoration to normality will need to be balanced against the known morbidity of untreated GH deficiency...
  7. ncbi Evidence for a link between IGF-I and cancer
    Paul J Jenkins
    Department of Endocrinology, St Bartholomew s Hospital, London EC1A 7BE, UK
    Eur J Endocrinol 151:S17-22. 2004
    ..The increased understanding of the molecular mechanisms and signalling pathways regulated by the GH/IGF-I axis has started to provide significant insights into the aetiology, prevention and therapy for a number of common cancers...
  8. ncbi Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly
    P J Jenkins
    Department of Endocrinology, St Bartholomew s Hospital, London, United Kingdom
    J Clin Endocrinol Metab 85:3218-21. 2000
    ..Serum IGF-I seems to be implicated in the development of colorectal neoplasia in acromegaly, although the exact mechanisms remain uncertain...
  9. ncbi Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors
    G Kaltsas
    Department of Endocrinology, St. Bartholomew's Hospital, London, United Kingdom EC1A 7BE
    J Clin Endocrinol Metab 86:895-902. 2001
    ..These data have implications not only for staging such tumors, but also for identifying patients who might benefit from treatment using either [(131)I]MIBG or radioactive somatostatin analogs...
  10. ncbi Increased levels of insulin-like growth factor binding protein-2 in sera and tumours from patients with colonic neoplasia with and without acromegaly
    F Miraki-Moud
    Department of Endocrinology, St. Bartholomew's Hospital, London, UK
    Clin Endocrinol (Oxf) 54:499-508. 2001
    ....
  11. ncbi Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration
    P J Jenkins
    Department of Endocrinology, St Bartholomew s Hospital, London, UK
    Clin Endocrinol (Oxf) 53:719-24. 2000
    ..However, it is uncertain whether the recommended dose intervals of 4 weeks and 10-14 days, respectively, are applicable to all patients...
  12. ncbi The expression and function of IGFBP-3 in normal and malignant breast tissue
    K McCarthy
    Breast Unit, Barts and the London Queen Mary School of Medicine, London, UK
    Anticancer Res 29:3785-90. 2009
    ..These findings suggest that IGFBP-3 may play a role in tumorigenesis, and that IGFBP-3 levels could be used in the future in cancer risk assessment/prevention or as markers of response to cancer treatments...
  13. ncbi Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines
    D Dworakowska
    Department of Endocrinology, Barts and the London School of Medicine, 68 Harley Street, London EC1A 7BE, UK
    Eur J Endocrinol 163:21-8. 2010
    ..It is suggested that patients with acromegaly have an increased risk of colorectal cancer and pre-malignant adenomatous polyps. However, the optimum frequency with which colonoscopic screening should be offered remains unclear...
  14. ncbi Colonic transit influences deoxycholic acid kinetics
    M J Veysey
    Gastroenterology Unit, Guy's Hospital Campus, London, England, UK
    Gastroenterology 121:812-22. 2001
    ..01). CONCLUSIONS: These data support the hypothesis that, by increasing DCA formation and absorption, prolongation of large bowel transit is a pathogenic factor in the formation of octreotide-induced gallstones...
  15. ncbi The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome
    P J Jenkins
    Department of Endocrinology, St Bartholomew s Hospital, West Smithfield, London, United Kingdom
    J Clin Endocrinol Metab 80:165-71. 1995
    ....
  16. ncbi Growth hormone deficiency and replacement in patients with treated Cushing's Disease, prolactinomas and non-functioning pituitary adenomas: effects on body composition, glucose metabolism, lipid status and bone mineral density
    A Colson
    Centre for Clinical Endocrinology, St. Bartholomew's Hospital, QMUL, London, UK
    Horm Res 66:257-67. 2006
    ..Because improvements in BMD occur later in PRL and CD patients, an extended trial of GH therapy may be indicated in those patients who were commenced on GH therapy as an additional treatment for reduced BMD...
  17. ncbi Lymphocytic hypophysitis: unusual features of a rare disorder
    P J Jenkins
    Department of Endocrinology, St Bartholomew s Hospital, London, UK
    Clin Endocrinol (Oxf) 42:529-34. 1995
    ..We suggest that the entire removal of such a mass is warranted both for accurate diagnosis and definitive treatment...
  18. ncbi The use of long-acting somatostatin analogues in acromegaly
    P J Jenkins
    Department of Endocrinology, St Bartholomew s Hospital, London, UK
    Growth Horm IGF Res 10:S111-4. 2000
    ..These results suggest that care needs to be taken to optimize the dose and dosage interval for each patient when commencing depot somatostatin analogue therapy...
  19. ncbi Selective parathyroid venous sampling in patients with complicated hyperparathyroidism
    C M Ogilvie
    Department of Endocrinology, St Bartholomew's Hospital, London, UK
    Eur J Endocrinol 155:813-21. 2006
    ..CONCLUSIONS: PVS is a valuable adjunct to MRI/CT and sestamibi scanning in selected patients with complicated hyperparathyroidism when performed in an experienced unit...
  20. ncbi Adrenal enlargement and failure of suppression of circulating cortisol by dexamethasone in patients with malignancy
    P J Jenkins
    Department of Endocrinology, St Bartolomew s Hospital, West Smithfield, London, UK
    Br J Cancer 80:1815-9. 1999
    ..This disturbance of the normal control of the HPA axis is unexplained and its functional significance remains uncertain...
  21. ncbi Cyclo-oxygenase-2 (COX-2) mRNA expression and hormone receptor status in breast cancer
    K McCarthy
    Breast Unit, St Bartholomew's Hospital, Barts and the London Queen Mary School of Medicine and Dentistry, West Smithfield, London EC1A 7EA, UK
    Eur J Surg Oncol 32:707-9. 2006
    ..There was no correlation between COX-2 mRNA levels and tumour size, grade, nodal status and presence of vascular invasion. CONCLUSIONS: COX-2 mRNA expression is increased in oestrogen and progesterone receptor negative breast cancers...
  22. ncbi Growth hormone and exercise: physiology, use and abuse
    P J Jenkins
    Department of Endocrinology, St Bartholomew s Hospital, London, UK
    Growth Horm IGF Res 11:S71-7. 2001
    ..The frequent and potentially severe side-effects associated with such 'doping' will be of increasing relevance to endocrinologists...
  23. ncbi Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR
    P J Jenkins
    Department of Endocrinology, St Bartholomew s Hospital, London, UK
    Horm Res 62:227-32. 2004
    ..This study prospectively determined the effects of the depot somatostatin analogue octreotide LAR on pituitary tumour size, GH and IGF-I levels and clinical symptoms in a cohort of previously untreated patients with acromegaly...
  24. ncbi Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients
    Amar Agha
    William Harvey Research Institute, Queen Mary University of London, London, UK
    Clin Endocrinol (Oxf) 66:72-7. 2007
    ..The effect of GH replacement on thyroid function in hypopituitary patients has hitherto been studied in small groups of children and adults with conflicting results...
  25. ncbi Effects of cisapride on gall bladder emptying, intestinal transit, and serum deoxycholate: a prospective, randomised, double blind, placebo controlled trial
    M J Veysey
    Gastroenterology Unit, Guy's Hospital Campus, GKT School of Medicine, Kings College, London, UK
    Gut 49:828-34. 2001
    ..Therefore, if changes in intestinal transit contribute to the development of octreotide induced gall bladder stones, enterokinetics such as cisapride may prevent their formation...
  26. ncbi Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]
    J J Mukherjee
    Department of Endocrinology, St Bartholomew's Hospital, West Smithfield, London EC1A 7BE, UK
    Clin Endocrinol (Oxf) 55:47-60. 2001
    ..It may be a valuable alternative or additional therapeutic option to the currently available conventional treatment modalities...
  27. ncbi Screening guidelines for colorectal cancer and polyps in patients with acromegaly
    P J Jenkins
    Department of Endocrinology, St Bartholomew's Hospital, West Smithfield, London EC1A 7BE, UK
    Gut 51:V13-4. 2002
  28. ncbi Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years
    C W le Roux
    Department of Endocrinology, St Bartholomew's and the Royal London School of Medicine and Dentistry, St Bartholomew's Hospital, London EC1A 7BE, UK
    Eur J Endocrinol 147:59-63. 2002
    ..No correlation was found between the individual changes in serum IGF-I and changes in serum PSA. CONCLUSIONS: These data are reassuring thus far regarding the safety of GH replacement in relation to the prostate in this patient group...
  29. ncbi Neurosurgical treatment of Nelson's syndrome
    P A Kelly
    Department of Endocrinology, St Bartholomew s and The Royal London Hospitals, London EC 1A 7BE, United Kingdom
    J Clin Endocrinol Metab 87:5465-9. 2002
    ....
  30. ncbi Local expression of insulin-like growth factor-I affects angiogenesis in colorectal cancer
    Stephen A Bustin
    Academic Department of Surgery, Barts and The London Queen Mary s School of Medicine and Dentistry, London, UK
    Tumour Biol 23:130-8. 2002
    ..The biological relevance of this finding is suggested by the significant association between local IGF-I mRNA levels and microvessel density in the colorectal cancers...
  31. ncbi Modulation of cortisol metabolism during treatment of acromegaly is independent of body composition and insulin sensitivity
    Giovanni V Frajese
    Department of Endocrinology, St Bartholomew's Hospital, King's College Hospital, London, UK
    Horm Res 61:246-51. 2004
    ..52.8 +/- 33.7). CONCLUSIONS: Modulation of cortisol metabolism during treatment of active acromegaly is dependent on changes in GH/IGF-1 status and is not influenced by any individual change in body composition or insulin sensitivity...
  32. ncbi The GH-IGF-I axis and breast cancer
    Christiana Laban
    Department of Breast Surgery, St Bartholomew's Hospital, West Smithfield, London EC1A 7BE, UK
    Trends Endocrinol Metab 14:28-34. 2003
    ..Here, we discuss the influence of the GH-IGF-I axis in normal mammary development and homeostasis, its putative role in breast tumorigenesis and its interactions with estrogen signalling...
  33. ncbi The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up
    Andrea M Isidori
    Department of Endocrinology, St. Bartholomew's Hospital, London EC1A 7BE, United Kingdom
    J Clin Endocrinol Metab 91:371-7. 2006
    ..These cases require a prolonged follow-up, review, and repetition of diagnostic tests and scans...
  34. ncbi Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas
    Y Sammy Woo
    Department of Endocrinology, St. Bartholomew's Hospital, London EC1A 7BE, United Kingdom
    J Clin Endocrinol Metab 90:4963-9. 2005
    ..Few patients with macroadenomas were cured by surgery. CONCLUSIONS: Pituitary macroadenomas causing Cushing's disease have biochemical features largely distinct from patients harboring microadenomas but represent one end of a continuum...
  35. ncbi Expression of 25-hydroxyvitamin D-1-alpha-hydroxylase, and vitamin D receptor mRNA in normal and malignant breast tissue
    Kathryn McCarthy
    Section of Endocrine Oncology, Department of Endocrinology, Barts and The London, Queen Mary School of Medicine, St Bartholomew s Hospital, London EC1A 6BT, UK
    Anticancer Res 29:155-7. 2009
    ..The decreased expression of 1alphaOHase in normal tissue from women with breast cancer may be important in their predisposition to the development of cancer...
  36. ncbi A single-center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide Autogel in patients with acromegaly previously treated with octreotide
    Phillip Kelly
    Department of Endocrinology, St Bartholomew s Hospital, West Smithfield, London, EC1A 7BE, United Kingdom
    Endocr Pract 16:191-7. 2010
    ..To evaluate the efficacy of lanreotide Autogel, a depot preparation of a long-acting somatostatin analogue, in patients with acromegaly who were previously treated with octreotide...
  37. ncbi IGF-1 levels, leg extensor power and physical performance after proximal femoral fracture
    Mark Barber
    Age Ageing 32:678-80. 2003
  38. ncbi The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy
    Nidhal Ali
    Department of Nuclear Medicine, St. Bartholomew's Hospital, London, UK
    Nucl Med Commun 27:165-9. 2006
    ..As a diagnostic agent it is preferable to 131I in differentiated thyroid carcinoma...